The Generic Oncology Drugs Market to see digitization being devised at a CAGR of

Posted by Steve Sharma on May 26th, 2022

The Generic Oncology Drugs Market is likely to grow immensely, i.e. reach US$ 41.5 Bn at a CAGR of 6%. Physical health apps are gaining popularity. They are inclusive of calorie trackers, step-counters, and exercise and nutrition-based apps. These apps are to be at the forefront with regards to capitalizing on those having chronic ailments like high blood pressure, heart diseases, or diabetes. This would be a significant arm of the healthcare industry.

Sales revenue from generic oncology drugs in 2020 was US$ 23 Bn, which is expected to surge to US$ 41.5 Bn by the end of 2031. Analysts at Persistence Market Research have also predicted the market to rise at a healthy CAGR of 6% over the next ten years.

Instances of cancer cases have risen exponentially across the globe. From diagnosis to treatment, all aspects of the disease are being researched extensively by numerous market players. Oncology treatment and drugs have proven to be very expensive for everyone, and this has been affecting overall treatment of cancer globally.

Like it? Share it!


Steve Sharma

About the Author

Steve Sharma
Joined: April 12th, 2021
Articles Posted: 445

More by this author